Rapid Plasma Kallikrein Inhibition Following Oral KVD900 Is Associated With Early Symptom Relief in Patients With Hereditary Angioedema

Duckworth EJ, Feener EP, Yea CM, Audhya P, Hampton SL, Smith MD

AAAAI 2022

KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results

Maetzel A, Smith MD, Duckworth EJ, Hampton SL, De Donatis GM, Murugesan N, Rushbrooke LJ, Li L, Francombe D, Feener EP, Yea CM

PMID: 35086692

Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.

Duckworth EJ, Murugesan N, Li L, Rushbrooke LJ, Lee DK, De Donatis GM, Maetzel A, Yea CM, Hampton SL, Feener EP

Clinical & Experimental Allergy

Relationship Between PGI-C Scale and Other PROs in KVD900 Trial in Hereditary Angioedema

Audhya P, Williams P, Yea CM

ACAAI 2021

A single on-demand treatment with orally administered KVD900 significantly slows progression and accelerates resolution of attacks in patients with hereditary angioedema (HAE): Results of a phase 2, placebo-controlled, double-blind cross-over trial

Aygören-Pürsün E, Zanichelli A, Cohn DM, Farkas H, Cancian M, Hakl R, Kinaciyan T, Magerl M, Martinez-Saguer I, Stobiecki M, Grivcheva-Panovska V, Kiani-Alikhan S, Krcmova I, Bernstein J, Manning M, Stroud C, Hanzlikova J, Li HH, Longhurst HJ, Melamed IR, Young P, Feener E, Iverson M, Maetzel A, Morten RM, Smith MD, Watissée MI, Williams P, Yea CM, Maurer M, Banerji A, and Riedl MA

EAACI 2021

Prevalence of hereditary angioedema with normal C1-inhibitor (nC1-HAE) in the United States: Results from a nationwide survey of HAE-treating physicians

Riedl MA, Danese M, Danese S, Ulloa J, and Maetzel A

EAACI 2021

On-demand Oral Treatment With KVD900 for HAE Attacks Achieves Rapid Exposure and Improves Patient Outcomes

Bernstein JA, Huamin LH, Yea CM, Maetzel A, Audhya P, Williams P, Banerji A, Riedl MA

ACAAI 2021

Current management of hereditary angioedema with normal C1-inhibitor (nC1-HAE) in the United States: Results from a nationwide survey of HAE-treating physicians

Riedl MA, Danese M, Danese S, Ulloa J, and Maetzel A

EAACI 2021

Oral plasma kallikrein inhibitor KV998052 improves arterial blood oxygenation in a murine model of acute respiratory distress syndrome (ARDS)

Murugesan N, Clermont AC, and Feener EP

EAACI 2021

Selective Factor XIIa inhibitor KV998083 protects mice against captopril induced vascular leakage and cleavage of high molecular weight kininogen

Clermont AC, Murugesan N, Edwards HJ, Whitney SA, Pethen SJ, Duckworth EJ, Hampton SL, Feener EP

EAACI 2021